Phase 4 Completed N=266 Randomized Single-blind Treatment

Bimatoprost 0.03% Versus Travoprost 0.004% in Patients Currently on Latanoprost 0.005%

Glaucoma · Hypertension

Source: ClinicalTrials.gov NCT00440011 ↗

Enrolled (actual)

266

Serious AEs

0.4%

Results posted

Sep 2008

Primary outcomePrimary: Intraocular Pressure (IOP) — 17; 17.5 mm Hg — p=0.024

Summary

Patients with glaucoma or ocular hypertension currently being treated with latanoprost 0.005%, and in need of additional IOP lowering, will be randomized to receive either bimatoprost 0.03% or travoprost 0.004% in place of latanoprost 0.005%

Outcome Measures

Outcome	Result	p-value
PRIMARY Intraocular Pressure (IOP)	17; 17.5	0.024 sig
SECONDARY Tolerability - Conjunctival Hyperemia	15; 22	—

Eligibility Criteria

Inclusion Criteria

Glaucoma or ocular hypertension in both eyes
Currently being treated with latanoprost 0.005% daily and in need of additional IOP-lowering
Best-corrected visual acuity of 20/100 or better in each eye
Visual field within 6 months of study entry

Exclusion Criteria

Secondary glaucoma
Active intraocular inflammation or macular edema
Intraocular surgery or laser surgery within the past 3 months

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00440011). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.